Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 5/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31647297 | 0.83 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KDM4ERECQLHSD17B10 | |
| SCHEMBL1993219 | 0.78 | KDM4E (0.49) | SMN1; SMN2ALDH1A1KDM4ETNF | |
| SCHEMBL1996973 | 0.77 | HRH4 (0.48) | LATS1KDM4CSMN1; SMN2ALDH1A1 | |
| SCHEMBL1993736 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1KDM4EHTTTNF | |
| SCHEMBL1989725 | 0.74 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1KDM4EHTTTNF | |
| SCHEMBL1991573 | 0.73 | KDM4E (0.51) | SMN1; SMN2ALDH1A1KDM4ERECQLHSD17B10 | |
| SCHEMBL1991935 | 0.73 | HSD17B10 (0.44) | SMN1; SMN2ALDH1A1KDM4EHTTRECQL | |
| SCHEMBL23122325 | 0.70 | ALDH1A1 (0.43) | LATS1KDM4CSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22718345 | 0.70 | ALDH1A1 (0.49) | LATS1KDM4CSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23202573 | 0.70 | ALDH1A1 (0.47) | LATS1KDM4CSMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | LATS1 1816/4885KDM4C 3498/4885SMN1; SMN2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.